Genetesis launches CardioFlux Membership program to revolutionize preventive cardiac care and eliminate heart disease.
Show it to me!

The standard of care
has changed for ischemic
heart disease.

Detect functionally significant ischemia at its earliest stages - all in as little as 5 minutes - with the world’s first clinically ready MCG machine.

CardioFlux Partners

Old Meets New

Trusted science meets brand new technology.

Magnetocardiography is the science that enables CardioFlux to measure the natural magnetic fields produced by the heart. We’re bringing 40 years of proven science into the heart of hospital workflows by improving the most limiting aspects of the technique.

More about MCG →
THE CARDIOFLUX PATHWAY

CardioFlux promises diagnostic
certainty without the burden.

Significantly earlier detection of chest pain patients means less time testing - and more time treating -
underlying disease.

Without CardioFlux

An ECG and initial troponin draw are taken.

A second troponin test is taken and results are compared with the first.

Downstream testing often requires waiting hours for technician availability and cardiology review.

Based on symptoms and risk factors, patients are often kept in an obs unit overnight before being sent home.

Stress testing requires 90 minutes to prepare and complete in a stress lab.

Although sent home, chest pain patients are often left with "inconclusive" results and "atypical" symptoms, often repeating the process of seeking a diagnosis in the near future.

With CardioFlux

An initial ECG and troponin draw are taken.

A CardioFlux scan is performed in five minutes and requires no stress.

A second troponin test is taken and results are compared with the first.

Decision

If necessary, a diagnosis is made. With fewer tests and less time spent waiting, efficient diagnosis means more effective triage and earlier discharge for chest pain patients.
PHYSICIAN TESTIMONIALS

Hear directly from doctors.

Over and over, physicians keep saying CardioFlux is the non-invasive functional test that they have been searching for.

Partnering with Us →
‍“[CardioFlux] will cut down the patient’s length of stay, cost to hospitals and it will be safer because it could cut down on risks like hospital acquired infections, radioactive dye and potential treadmill injury.”

Dr. Margarita Pena, MD, FACEP

Observation Unit, Ascension St. John Hospital

"We are working tirelessly to provide biomagnetic solutions to solve some of the world's most pressing healthcare challenges.

Vineet Erasala

Co-Founder & COO, Genetesis